| Expression pattern: |
UP |
| Associated gene: |
FUS, EIF4A3, TAZ, CCN1, CCN2, YAP |
| Associated microRNA: |
- |
| Biological function: |
promotes CRC cell growth/proliferation; exacerbates DSS-induced colitis; promotes colitis-associated tumorigenesis |
| Molecular mechanism: |
circHIPK2 (mediated by FUS) binds EIF4A3 to enhance TAZ mRNA translational efficiency, increasing YAP/TAZ target gene transcription (CCN1, CCN2) and modulating Hippo signaling |
| Biological pathway or process: |
Hippo/YAP (promotes); proliferation (promotes); cell cycle (promotes); ceRNA regulation (other) |
| Detected method: |
Q
M
|
| Validation methods: |
Microarray; Bioinformatics Analysis; RT-qPCR; Clinical Sample Validation; Back-Splice Junction PCR / divergent primers PCR; Sanger Sequencing; RNase R Treatment; Nuclear-Cytoplasmic Fractionation; FISH / smFISH; RNA-seq; Transfection; MTT; Colony Formation Assay; Cell Cycle Assay; Western Blot; IF (Immunofluorescence); RNA Pull-Down; RIP (RNA Immunoprecipitation); Luciferase Reporter Assay; Actinomycin D / DRB Stability Assay; In Vivo Animal Model; IHC (Immunohistochemistry); H&E Staining |
| Clinical significance: |
potential biomarker for IBD and CRC |
| Description: |
circHIPK2 is up-regulated in IBD and CRC. It promotes intestinal epithelial/CRC cell growth by recruiting EIF4A3 (with FUS supporting circHIPK2 biogenesis) to enhance TAZ translation, thereby activating Hippo/YAP/TAZ downstream targets such as CCN1 and CCN2; circHipk2 knockdown worsens DSS colitis but reduces colitis-associated tumorigenesis. |
| Confidence score: |
0.8826 |